Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Nifedpine in Compounded Oral and Topical Preparations

Author(s):  McCluskey Susan V, Brunn Gregory J

Issue:  Mar/Apr 2011 - Volume 15, Number 2
View All Articles in Issue

Page(s):  166-169

Nifedpine in Compounded Oral and Topical Preparations Page 1
Nifedpine in Compounded Oral and Topical Preparations Page 2
Nifedpine in Compounded Oral and Topical Preparations Page 3
Nifedpine in Compounded Oral and Topical Preparations Page 4

Download in electronic PDF format for $75

Abstract:  The purpose of this study was to evaluate nifedipine oral and topical compounding formulas and procedures. Topical preparations were compounded in Plastibase 50 W, using combinations of two drug sources and four types of light exposure. Oral preparations were compounded using combinations of two drug sources, two types of light exposure, and four suspending vehicles. Drug sources consisted of the contents of commercial nifedipine soft-gelatin capsules and nifedipine powder USP. Light exposures were ambient, red-shaded, goldshaded fluorescent light, or a combination of ambient and gold-shaded fluorescent light. Topical formulations were assessed for potency, uniformity, and usability characteristics such as acceptable look and feel of the preparation. Oral formulations were assessed for potency, uniformity, and usability characteristics, such as acceptable look and taste of the preparation. Preparations which were compounded, in entirety, under gold-shaded fluorescent light with nifedipine powder USP as the drug source resulted in a potency of 90% to 110% of intended value. Preparations that were exposed to ambient or red-shaded fluorescent light at any time in the compounding procedure resulted in subpotent preparations. Nifedipine is sensitive to certain wavelengths of light resulting in rapid degradation. When exposed to fluorescent room light, significant degradation may occur in a time frame less than what may be required to compound a preparation, necessitating the need for compounding to take place under a spectrum of light that will not degrade the drug. Gold fluorescent lighting appears to prevent nifedipine degradation during compounding procedures. Concerning the drug source, the use of commercial nifedipine soft gelatin capsules was problematic, while nifedipine powder USP is a suitable choice for the active pharmaceutical ingredient.

Related Keywords: nifedipine, calcium channel blocker, hypertension, high blood pressure, angina, photodegradation, degradation, light exposure, potency, stability, topical preparations, oral preparations, light sensitivity, vehicle

Related Categories: PEER-REVIEWED, STABILITIES, COMPATIBILITIES, CARDIOLOGY, DOSAGE FORMS/DRUG CARRIERS

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Nifedpine in Compounded Oral and Topical Preparations
McCluskey Susan V
, Brunn Gregory J
Mar/Apr 2011
Pg. 166-169

Current Topical Treatments in Wound Healing - Part 1
Helmke Christopher D
Jul/Aug 2004
Pg. 269-274

Quality Control: Photostability of Compounded Preparations
Allen Loyd V Jr
May/Jun 2020
Pg. 200-205

Novel Approaches to Topical Psoriasis Therapy
Koyama Gregory
, Liu Jenny, Scaffidi Alyse, Khazraee Maryam, Epstein Benjamin
Sep/Oct 2015
Pg. 357-365

Stability of Compounded Topical Nifedipine in Cream, Gel, and Ointment Bases
Teimouri Arezou
, Yeung Pollen, Agu Remigius U
Jul/Aug 2021
Pg. 344-351

Stability of Clopidogrel in Three Extemporaneously Compounded Oral Liquid Preparations
Yamreudeewong Weeranuj
, Dolence Eric Kurt, Teixeira M Glaucia
Sep/Oct 2011
Pg. 435-437

Women's Oral Health: Is There a Hormonal Link?
Preckshot John
Jan/Feb 2004
Pg. 10-14

Quality Control Analytical Methods: End-preparation Assessments and Tests for Compounded Sterile Preparations
McElhiney Linda F
Jul/Aug 2013
Pg. 307-311

Compounding Enclosures: Ensuring Safety During the Preparation of Sterile and Nonsterile Formulations
Ashe Krystina
, Baskett Dustin
Sep/Oct 2018
Pg. 387-398

Drug-release Assessment of Compounded Topical Nifedipine and Diltiazem in Commonly Used Bases for Wound Healing
Teimouri Arezou
, Yeung Pollen, Agu Remigius U
Nov/Dec 2020
Pg. 501-508

Physicochemical Stability of Extemporaneously Prepared Methylcobalamin Injections in the Presence and Absence of Preservative and the Impact of Light Exposure
Ip Kendice
, Banov Daniel, Bassani Gus, Morgan Latisha
Mar/Apr 2019
Pg. 167-175

Basics of Compounding Biotechnologic Preparations
Allen Loyd V Jr
Jan/Feb 2002
Pg. 34-37

Utilization of Compounded Medications in an Oral Medicine Practice
Stock Shannon
, Rubino Katie, Woo Sook-Bon, Margolis Arthur, Thomas Irena, Aboalela Ali, Treister Nathaniel
Mar/Apr 2016
Pg. 155-158

Sterile Basics of Compounding: Particulates in Parenteral Preparations: Sources, Minimization, and Detection
Allen Loyd V Jr
May/Jun 2022
Pg. 219-228

A Compendium of Compounding Agents and Formulations, Part 4: Nifedipine and Pentoxifylline
Riepl Mike
Jul/Aug 2022
Pg. 270-274

Stability of Commercially Available Grape and Compounded Cherry Oral Vancomycin Preparations Stored in Syringes and Cups
Kirk Loren
, Lewis Paul, Luu Yao, Brown Stacy
Mar/Apr 2016
Pg. 159-163

Nifedipine 1-mg/500-mg Oral Powder
Allen Loyd V Jr
Sep/Oct 2011
Pg. 422

Nifedipine 10-mg/mL Oral Suspension
Allen Loyd V Jr
Sep/Oct 2011
Pg. 423

Nifedipine 4-mg/mL Oral Liquid
Allen Loyd V Jr
Jul/Aug 2006
Pg. 303

Intravenous Admixture Preparation Considerations, Part 9-A: Error Prevention in Intravenous Admixture Preparation
Allen Loyd V Jr
Mar/Apr 2021
Pg. 131-139

Return to Top